FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.

Palmitoleic acid is a constituent of the triglycerides of human adipose tissue. Palmitoleic acid-based diets raise low-density lipoprotein cholesterol and diminish high-density lipoprotein cholesterol.

SR 202 is a selective PPARγ antagonist which attenuates troglitazone-induced PPARγ transcriptional activity with IC50 value of 140μM. It inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo and improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.

Pemafibrateis a selective PPARα modulator (SPPARMα) that has antihyperlipidaemic activity.

BMS-687453 is a potent and selective PPARα agonist, with an EC50 of 10 nM for human PPARα and 410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.

Elafibranor is an agonist of PPARα and PPARδ with EC50 values of 45 nM and 175 nM, respectively. Elafibranor also attenuates nonalcoholic steatohepatitis without fibrosis worsening.

Balaglitazone is a partial agonist of PPAR-γ.